Whether you're nearing retirement or have many more years in the workforce ahead of you, it's important to establish an investing strategy that aligns with your goals and risk tolerance. And part of ...
Viking Therapeutics advances its dual GLP-1/GIP obesity drug into Phase 3 trials, entering a $100 billion weight loss market. Applied Digital's $7 billion CoreWeave partnership transforms it into an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback